Description
Cagrilintide is an investigational, long-acting synthetic analog of the pancreatic hormone amylin being developed for weight management and type 2 diabetes.
How It Works
-
Amylin Receptor Agonist: It mimics native amylin by activating specific receptors in the hindbrain and brainstem.
-
Satiety and Emptying: It delays gastric emptying and promotes a strong sense of fullness, reducing overall food intake.
-
Complementary Action: When paired with the GLP-1 receptor agonist semaglutide (known as CagriSema), it targets separate biological pathways for additive appetite suppression and enhanced weight loss.
Clinical Status and Efficacy
-
Monotherapy: Clinical trials show cagrilintide alone results in meaningful, dose-dependent weight reduction.
-
Combination Therapy (CagriSema): Phase 3 trials evaluating the combination of cagrilintide and semaglutide demonstrate superior reductions in body weight and improvements in cardiometabolic markers compared to individual components.
-
Approval Status: It remains an investigational therapy undergoing ongoing regulatory review and clinical evaluation.
Side Effects and Safety
-
Gastrointestinal: Common adverse events are primarily gastrointestinal, including nausea, vomiting, and diarrhea, aligning with the profile of metabolic peptide treatments
- Keep sealed in the original Vial.
- Keep dry away from moisture.
- Store cold at 2–8 °C (standard refrigerator temperature).
- Store frozen for longer term storage
- Keep refrigerated to maintain quality. Do not freeze.
- Follow your laboratory rules for handling and how long it stays fresh.
For in-vitro research and laboratory use only. Not intended for human or veterinary use. By purchasing, you confirm you are a qualified researcher and will use this compound in accordance with all applicable laws and regulations.
Reviews
There are no reviews yet.